South San Francisco, United States
3T Biosciences, founded in 2017 and headquartered in the United States, is an emerging player in the Biopharma and Biotechnology sectors. The company is dedicated to revolutionizing immunotherapy by developing next-generation therapies aimed at treating solid tumors and other immune-mediated diseases. Their unique approach harnesses the immune system's inherent ability to identify and eradicate cancer cells, potentially offering safer and more effective treatments.
Recently, 3T Biosciences secured a $40.00M Series A investment on 01 August 2022, led by prominent investors Lightspeed Venture Partners and Westlake Village BioPartners. This substantial financial backing underscores the investor confidence in the company's cutting-edge technology and its potential to bring transformative solutions to patients with difficult-to-treat cancers.
3T's vision aligns with the growing demand for advanced immunotherapies, positioning it strategically within the evolving Health Care industry.
